Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Gastroenterology · Barrett's Esophagus

Barrett’s Esophagus: Understanding Risk and Prevention

At a Glance

Barrett's esophagus is a precancerous condition caused by chronic acid reflux, but the risk of it progressing to esophageal cancer is very low. Regular screening is for high-risk individuals, and abnormal cell changes can be safely treated during a standard endoscopy to prevent cancer.

For many people with chronic reflux, the greatest fear is that it will lead to cancer. While there is a link between long-term GERD and a condition called Barrett’s Esophagus, it is important to understand that the risk for any single individual remains remarkably low. Barrett’s is a condition where the body, in an attempt to protect itself from chronic acid injury, replaces the normal lining of the esophagus with a tougher, intestinal-like tissue [1].

Who Needs Screening?

Not everyone with heartburn needs to be screened for Barrett’s. Medical guidelines from the ACG and AGA recommend screening only for those at the highest risk. Usually, this means people who have had chronic GERD symptoms for at least 5 years AND have at least three of the following risk factors [2][3]:

  • Age: Over 50 years old.
  • Sex: Male.
  • Race: Non-Hispanic White.
  • Lifestyle: A current or past history of smoking.
  • Body Type: Central obesity (carrying extra weight around the midsection).
  • Family History: A first-degree relative (parent or sibling) with Barrett’s or esophageal cancer.

Understanding the Risk

If you are diagnosed with Barrett’s, it is a “precancerous” condition, but it is not cancer. The vast majority of people with Barrett’s will never develop esophageal cancer.

  • Low Progression Rate: For patients with non-dysplastic Barrett’s (meaning the cells look stable), the risk of progressing to cancer is only about 0.2% to 0.5% per year [4].
  • Length Matters: The risk of progression is also linked to the length of the Barrett’s segment; segments longer than 3 cm generally carry a slightly higher risk than shorter segments [5][6].

Surveillance and Monitoring

If you have Barrett’s, your doctor will put you on a surveillance schedule. This involves a regular endoscopy with biopsies to “check in” on the cells.

  • Non-dysplastic Barrett’s: The standard recommendation is an endoscopy every 3 to 5 years [7][8].
  • Low-Grade Dysplasia: If the cells begin to show early “angry” changes (dysplasia), your doctor may recommend more frequent check-ups or treatment to prevent further progression [5].

Treatment Before Cancer

If the cells reach a point where they are considered high-risk (high-grade dysplasia), we no longer have to rely on major surgery. Modern endoscopic eradication therapies allow doctors to treat the area during a standard endoscopy [9]:

  • Endoscopic Mucosal Resection (EMR): The doctor physically removes any visible bumps or abnormal areas [10].
  • Radiofrequency Ablation (RFA): The doctor uses heat (radio waves) to “burn away” the thin layer of abnormal Barrett’s tissue, allowing healthy, normal tissue to grow back in its place [11][12].

These treatments are highly effective and have significantly reduced the need for more invasive surgeries [9]. For most patients, a diagnosis of Barrett’s is simply a signal to stay vigilant with regular monitoring.

Common questions in this guide

Who should be screened for Barrett's esophagus?
Screening is typically recommended for individuals who have had chronic GERD symptoms for at least five years and have three or more risk factors. These factors include being over 50, male, a current or former smoker, carrying extra weight around the midsection, or having a family history.
Does having Barrett's esophagus mean I will get cancer?
No, the vast majority of people with Barrett's esophagus will never develop esophageal cancer. If your cells are stable (non-dysplastic), the risk of progressing to cancer is only about 0.2% to 0.5% per year.
What does non-dysplastic Barrett's mean on my pathology report?
Non-dysplastic means that while the tissue in your esophagus has changed due to chronic acid exposure, the cells look stable. They do not show any early precancerous changes, meaning your risk of progression is very low.
How often do I need an endoscopy if I have Barrett's esophagus?
If you are diagnosed with non-dysplastic Barrett's, the standard medical recommendation is to undergo a surveillance endoscopy every three to five years to monitor the tissue for any abnormal changes.
What happens if my Barrett's esophagus gets worse?
If the cells show high-risk changes, known as dysplasia, your doctor can treat them during a standard endoscopy. Procedures like Radiofrequency Ablation (RFA) or Endoscopic Mucosal Resection (EMR) can remove or destroy the abnormal tissue before it turns into cancer.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my age, sex, and history of reflux, do I meet the official ACG criteria for Barrett's screening?
  2. 2.If I have Barrett's, was it described as 'non-dysplastic,' or were there signs of 'low-grade' or 'high-grade' dysplasia?
  3. 3.What is the length of my Barrett’s segment? Is it considered a 'short-segment' or 'long-segment,' and how does that affect my risk?
  4. 4.If my Barrett's is non-dysplastic, can we set a reminder for my next surveillance endoscopy in 3 to 5 years?
  5. 5.If dysplasia is found, am I a candidate for endoscopic treatments like radiofrequency ablation (RFA) instead of surgery?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Epidemiology of Barrett's Esophagus and Esophageal Carcinoma.

    Fabian T, Leung A

    The Surgical clinics of North America 2021; (101(3)):381-389 doi:10.1016/j.suc.2021.03.001.

    PMID: 34048759
  2. 2

    AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review.

    Muthusamy VR, Wani S, Gyawali CP, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022; (20(12)):2696-2706.e1 doi:10.1016/j.cgh.2022.06.003.

    PMID: 35788412
  3. 3

    Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.

    Kamboj AK, Katzka DA, Iyer PG

    Gastrointestinal endoscopy clinics of North America 2021; (31(1)):27-41 doi:10.1016/j.giec.2020.08.002.

    PMID: 33213798
  4. 4

    Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.

    Shaheen NJ, Falk GW, Iyer PG, et al.

    The American journal of gastroenterology 2022; (117(4)):559-587 doi:10.14309/ajg.0000000000001680.

    PMID: 35354777
  5. 5

    Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.

    Klaver E, Bureo Gonzalez A, Mostafavi N, et al.

    United European gastroenterology journal 2021; (9(8)):929-937 doi:10.1002/ueg2.12114.

    PMID: 34228885
  6. 6

    Should All Patients with Barrett's Esophagus Receive Ablation?

    Shafa S, Carroll JE

    Current gastroenterology reports 2023; (25(6)):115-121 doi:10.1007/s11894-023-00869-6.

    PMID: 37204654
  7. 7

    Barrett Esophagus: A Review.

    Sharma P

    JAMA 2022; (328(7)):663-671 doi:10.1001/jama.2022.13298.

    PMID: 35972481
  8. 8

    Evaluating Cost-Effectiveness of 85 Endoscopic Surveillance Strategies of Nondysplastic Barrett's Esophagus.

    Vissapragada R, Bulamu NB, Yazbeck R, et al.

    Journal of gastroenterology and hepatology 2026; (41(3)):992-1000 doi:10.1111/jgh.70238.

    PMID: 41553019
  9. 9

    The evolution of endoscopic therapy for Barrett's esophagus.

    Condon A, Muthusamy VR

    Therapeutic advances in gastrointestinal endoscopy 2021; (14()):26317745211051834 doi:10.1177/26317745211051834.

    PMID: 34708204
  10. 10

    Long-term durability of radiofrequency ablation for Barrett's-related neoplasia.

    Haidry R, Lovat L

    Current opinion in gastroenterology 2015; (31(4)):316-20 doi:10.1097/MOG.0000000000000190.

    PMID: 26039723
  11. 11

    Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett's esophagus may not be benign.

    Cameron GR, Desmond PV, Jayasekera CS, et al.

    Endoscopy international open 2016; (4(8)):E849-58 doi:10.1055/s-0042-109608.

    PMID: 27540572
  12. 12

    Endoscopic therapy for Barrett's esophagus and early esophageal cancer: Where do we go from here?

    Singh T, Sanaka MR, Thota PN

    World journal of gastrointestinal endoscopy 2018; (10(9)):165-174 doi:10.4253/wjge.v10.i9.165.

    PMID: 30283599

This information about Barrett's esophagus is for educational purposes only and does not replace medical advice. Always consult a gastroenterologist to discuss your specific screening needs and endoscopy results.

Get notified when new evidence is published on gastroesophageal reflux disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.